Jagsonpal Pharma Q1 FY27: Revenue Up 9%, PAT Up 22%, Cash Reserves at ₹1,700 Mn
Jagsonpal Pharmaceuticals Limited reported Q1 FY27 results with revenue up 9% YoY to ₹822 Mn and PAT up 22% YoY to ₹132 Mn. Operating EBITDA increased 21% to ₹191 Mn. Cash reserves stood at ₹1,700 Mn. The company completed an 85% stake acquisition in Aequitas Healthcare.
The reported strong financial performance, coupled with a strategic acquisition, is expected to have a significant positive impact on the company's growth trajectory and market standing.
The company reported strong year-on-year growth in revenue, operating EBITDA, and PAT, alongside a healthy cash balance. The successful acquisition of Aequitas Healthcare further strengthens its market position and future growth prospects.
Jagsonpal Pharmaceuticals Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a strong start to FY27 with revenue increasing by 9% year-on-year to ₹822 Mn and Profit After Tax (PAT) growing by 22% to ₹132 Mn. Operating EBITDA also saw a significant jump of 21% year-on-year to ₹191 Mn, with EBITDA margins expanding by 241 basis points to 23.2%. The company maintained a robust cash balance of ₹1,700 Mn, even after a ₹400 Mn share buyback. This financial strength was highlighted as a key enabler for strategic initiatives, including the recent acquisition of a controlling stake (85%) in Aequitas Healthcare. The acquisition, funded by internal accruals, marks Jagsonpal's entry into the hospital supplies segment and is expected to contribute over ₹100 Mn in EBITDA by Year 2 post-integration. The company outperformed the broader Indian pharmaceutical market, with Pharmarack reporting 18.9% growth for Jagsonpal compared to 11.6% for the IPM, leading to a four-rank improvement to #88 in the Indian pharmaceutical market. Manish Gupta, Managing Director and CEO, expressed confidence in sustaining profitable growth and pursuing value-accretive inorganic opportunities.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.